C
보로노이
310210KOSDAQ41.5 / 100
Reference Date: 2026-10-23
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Boronoai is a biotech company specializing in the development of targeted therapies for cancers such as lung and breast cancer, leveraging its in-house research facilities and AI platforms to conduct early clinical trials and pursue a global licensing-out (License-Out) business model. The company focuses on kinase inhibitors, leveraging its expertise and accelerated development timelines to build competitive pipelines.
Number of Employees
149people
Average Salary
81.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-50.18Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
57.37Industry Average 100.005.0Point
Lower than industry avg (good)
Trend 2023~20251.5 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
0.0 / 3
Avg ▼32.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -52.7% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (11%, downtrend)
Current 131,800Won52-week high 363,50052-week low 100,800
1-month return2.0Point
1m -5.59% (slight drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)2026-10-20
- Neutral기업설명회(IR)개최2026-10-13
- Neutral주요사항보고서(자기전환사채만기전취득결정)2026-10-08
- Neutral[기재정정]반기보고서 (2026.06)2026-10-02